🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Mobile Vehicle-Based Delivery of Lenacapavir Pre-Exposure Prophylaxis in Los Angeles County

Recruitingn/aAges 18 Years - anyAllUniversity of California, Los Angeles
NCT07467018 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This project evaluates the implementation strategy of the delivery of lenacapavir pre-exposure prophylaxis (LEN PrEP) - a newly available long-acting, injectable medication for human immunodeficiency virus (HIV) prevention - via a mobile health van model for people who are unstably housed in Los Angeles County (LAC). People who are unhoused or are facing housing instability experience significant barriers to accessing HIV prevention care in traditional clinic settings. In 2022, approximately 13% of newly diagnosed HIV cases in LAC were experiencing homelessness, a 36% increase over the prior period. The study will work with the University of California, Los Angeles (UCLA) Health's Homeless Healthcare Collaborative (HHC), which operates mobile health vans staffed by clinicians, social workers, and community health workers, to bring LEN PrEP directly to community settings, such as shelters

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Being reached for mobile health services by a UCLA HHC mobile van * ≥18 years of age * Able to provide informed consent * English or Spanish-speaking * Willing and able to comply with study procedures * HIV unknown or negative status and HIV negative based on rapid 4th generation Ag/Ab test on the day of enrollment * At-risk for HIV, based on clinician assessment (based on CDC guidelines; includes any individual requesting PrEP, regardless of reported risk factors for HIV) * Pregnant and breastfeeding women/people can be offered LEN with counseling about benefits and risks. Exclusion Criteria: * Any clinical or psychosocial condition or prior therapy that, in the opinion of the investigator, would make the participant unsuitable for the study or unable to take LEN PrEP * Known hypersensitivity to the study drug, the metabolites, or formulation excipient * BMI \<35 kg/m2 (77 pounds) * On oral or other long-acting PrEP and unwilling to discontinue * Already taking LEN for HIV prevention * Known HIV diagnosis or positive 4th generation HIV Ab/Ag test (on day of enrollment) or subsequent lab-based confirmatory testing.
💊

What it tests

  • Community-based healthcare delivery
  • Lenacapavir
📍

Where

1 site
UCLA Health Homeless Healthcare Collaborative
Santa Monica, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy